Goldman Sachs Resumes Coverage of Iovance Biotherapeutics with Buy Rating
On September 24, 2026, Goldman Sachs analyst Andrea Newkirk resumed coverage on biotech firm Iovance Biotherapeutics (NASDAQ: IOVA), assigning a 'buy' rating and setting a price target of $15 per share. This move contributed to an almost 6% surge in the company's stock during trading hours. The recommendation was based partly on strong second-quarter performance, where its only commercialized drug, Amtagvi, generated $91 million in sales by treating 150 patients. Newkirk highlighted that operational challenges such as availability are being resolved and cited a proprietary survey showing robust interest for Amtagvi as a second-line treatment for melanoma. The FDA approved the therapy early in 2024, marking an important milestone after years of development hurdles.
Tickers: $IOVA
Topics: Biotech Cancer Therapies Stock Analysis